246 related articles for article (PubMed ID: 27240941)
41. Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer.
Stover JT; Moore RA; Davis K; Harrison MR; Armstrong AJ
Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):161-6. PubMed ID: 25777155
[TBL] [Abstract][Full Text] [Related]
42. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
[TBL] [Abstract][Full Text] [Related]
43. Re: Shusuke Akamatsu, Masashi Kubota, Ryuji Uozumi, et al. Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer. Eur Urol Oncol 2019;2:320-328.
Mazzone E; Karakiewicz PI
Eur Urol Oncol; 2019 May; 2(3):338-339. PubMed ID: 31200851
[No Abstract] [Full Text] [Related]
44. Metabolic and prostate-specific antigen response after abiraterone acetate withdrawal: a new clinical scenario for castration-resistant prostate cancer?
Caffo O; Palermo A; Veccia A; Maines F; Chierichetti F; Galligioni E
Clin Genitourin Cancer; 2013 Dec; 11(4):e10-4. PubMed ID: 23810439
[No Abstract] [Full Text] [Related]
45. Re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032: Interpreting the Effect of Ipilimumab Following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.
Ludmir EB; McCaw ZR; Wei LJ
Eur Urol; 2021 Jan; 79(1):e10-e11. PubMed ID: 33109378
[No Abstract] [Full Text] [Related]
46. Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.
Petrioli R; Francini E; Laera L; Fiaschi AI; Ponchietti R; Roviello G
Cancer Chemother Pharmacol; 2015 Sep; 76(3):439-45. PubMed ID: 26082421
[TBL] [Abstract][Full Text] [Related]
47. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
Ryan CJ; Smith MR; Fizazi K; Saad F; Mulders PF; Sternberg CN; Miller K; Logothetis CJ; Shore ND; Small EJ; Carles J; Flaig TW; Taplin ME; Higano CS; de Souza P; de Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE;
Lancet Oncol; 2015 Feb; 16(2):152-60. PubMed ID: 25601341
[TBL] [Abstract][Full Text] [Related]
48. Re: Qing Cheng, William Butler, Yinglu Zhou, et al. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy. Eur Urol. 2022;81:446-55.
Heidegger I; Pircher A
Eur Urol; 2022 Jun; 81(6):e145. PubMed ID: 35287980
[No Abstract] [Full Text] [Related]
49. There Is Now Compelling Evidence to Further Evaluate Lower Doses of Abiraterone Acetate in Men With Metastatic Prostate Cancer: It Should Be Safer, May Be as Effective and Less Expensive.
Velho PI; Eisenberger MA
J Clin Oncol; 2018 Oct; 36(30):3059-3060. PubMed ID: 30188787
[No Abstract] [Full Text] [Related]
50. Re: Redirecting Abiraterone Metabolism to Fine-Tune Prostate Cancer Anti-Androgen Therapy.
Taneja SS
J Urol; 2016 Nov; 196(5):1447. PubMed ID: 27751453
[No Abstract] [Full Text] [Related]
51. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
52. Reply to Tuomas Mirtti and Tero Aittokallio's Letter to the Editor re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40. Clinical Utility of Trial-estimated Prognostic Models.
Seyednasrollah F; Mahmoudian M; Rautakorpi L; Hirvonen O; Laitinen T; Jyrkkiö S; Elo LL
Eur Urol; 2017 Sep; 72(3):e70-e71. PubMed ID: 28499619
[No Abstract] [Full Text] [Related]
53. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients.
Carton E; Noe G; Huillard O; Golmard L; Giroux J; Cessot A; Saidu NE; Peyromaure M; Zerbib M; Narjoz C; Guibourdenche J; Thomas A; Vidal M; Goldwasser F; Blanchet B; Alexandre J
Eur J Cancer; 2017 Feb; 72():54-61. PubMed ID: 28027516
[TBL] [Abstract][Full Text] [Related]
54. Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.
Binder M; Zhang BY; Hillman DW; Kohli R; Kohli T; Lee A; Kohli M
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27409606
[TBL] [Abstract][Full Text] [Related]
55. Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients.
Xu XS; Ryan CJ; Stuyckens K; Smith MR; Saad F; Griffin TW; Park YC; Yu MK; Vermeulen A; Poggesi I; Nandy P
Clin Cancer Res; 2015 Jul; 21(14):3170-7. PubMed ID: 25829400
[TBL] [Abstract][Full Text] [Related]
56. Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.
Conteduca V; Caffo O; Lolli C; Aieta M; Scarpi E; Bianchi E; Maines F; Schepisi G; Salvi S; Massari F; Carrozza F; Veccia A; Chiuri VE; Campadelli E; Facchini G; De Giorgi U
Prostate; 2017 Jun; 77(9):1012-1019. PubMed ID: 28429372
[TBL] [Abstract][Full Text] [Related]
57. Early use of abiraterone and radium-223 in metastatic prostate cancer.
Hindié E; Morgat C
Lancet Oncol; 2019 May; 20(5):e229. PubMed ID: 31044706
[No Abstract] [Full Text] [Related]
58. Early use of abiraterone and radium-223 in metastatic prostate cancer.
Cursano MC; Santini D; Iuliani M; Paganelli G; De Giorgi U
Lancet Oncol; 2019 May; 20(5):e228. PubMed ID: 31044705
[No Abstract] [Full Text] [Related]
59. Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.
Parente P; Parnis F; Gurney H
Asia Pac J Clin Oncol; 2014 Sep; 10(3):205-15. PubMed ID: 24750803
[TBL] [Abstract][Full Text] [Related]
60. Reply to John T. Leppert and James D. Brooks' Letter to the Editor re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018;74:146-54.
Mahal BA; Yang DD; Nguyen PL
Eur Urol; 2018 Nov; 74(5):e112-e113. PubMed ID: 30029822
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
